Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression
the ONA take:
Cholesterol-lowering statin drugs were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT), according to a clinical trial from Dana-Farber Cancer Institute.
In the study, men who had been taking statins since the start of ADT went a median of 27.5 months before experiencing disease progression, compared with 17.4 months for men who were not taking statins.
Laboratory studies focusing on the SLCO2B1 protein found that the protein helps a variety of drugs and hormones enter cells, including both statin drugs and dehydroepiandrosterone sulfate (DHEAS), a precursor of testosterone, the hormone that spurs prostate cancer cell growth.
Using laboratory-grown prostate cancer cell lines, the researchers found that statin drugs monopolized available SLCO2B1 thereby depriving prostate cancer cells of the hormones they need to grow.
The trial involved 926 patients, and 70% of participants experienced disease progression during a 6-year period.
Although this mechanism by which statins may work in prostate cancer can improve patient outcomes, the researchers state that further study is needed to validate their findings.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with ADT.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|